The A2/AA/6/60 virus, which was adapted to grow to 25 C in chick kidney cell culture and embryonated eggs, has been observed in mice to show a significant reduction in virulence (1, 2).
The same virus cultured at 25 C in primary bovine kidney cells became available for clinical evaluation. The vaccine virus, A2/AA/6/60, was originally isolated from the nasopharynx of a patient with influenza and successively maintained in serum-free medium. The virus was first passed four times at 36 C and subsequently eight times at 25 C by Hunein F. Maassab of the School of Public Health, University of Michigan. Two additional passages and preparation of the vaccine for the trial in man were made at the Respiratory Virus Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health. The 15th passage virus vaccine was used in these studies. The infectivity titer of the vaccine in monkey kidney cell culture was 106 5 median tissue culture infective dose (TCID,0)/ml, and the hemagglutinating titer was 1:4. Volunteers were healthy male inmates at the Maryland House of Correction, Jessup, Md. Thirteen men with a low to moderate level of antibody for A2/AA/6/60 were enrolled in two separate studies. A total of 2 ml of the vaccine was administered into each man: 0.5 ml delivered into each nostril by a pipette and 1.0 ml sprayed onto the posterior pharynx. Physical examination and collection of throat washings for virus isolation were performed daily for 10 consecutive days. Base-line and followup samples of serum, nasal washing, sputum, and saliva for antibody titrations were obtained. Neutralizing antibody titers were determined against 100 TCID50 of the virus in monkey kidney cell cultures. Virus isolation and titration of the vaccine were also carried out in this cell culture. Nasal washings were concentrated two to five times either by lyophilization or by dialysis against Carbowax 20-M prior to antibody titration. Immunoglobulin A and G (IgA, IgG) concentrations in nasal washing, sputum, and saliva samples were assayed on immunodiffusion agar plates.
The first study was conducted with five men whose serum titers ranged from 1:16 to 1: 128. Diluted vaccine containing approximately 64,000 TCID50 was administered. No one developed clinical illness or excreted the virus. Antibody titer elevations were not detected in postvaccination sera.
The second study was performed with eight men who had lower serum titers, and one man 
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